Dublin-headquartered pharmaceutical firm Amryt has reported an operating loss of $12m for the second quarter, despite a 22% rise in revenues in the period.

However the firm said the "positive momentum" of 2019 had continued, as it forecast full year revenues of $170m-175m (up 10.3-13.5% year-on-year).

Amryt produces a range of medicines, including drugs for cholesterol disorders and leptin deficiencies.

It is also developing a drug to treat a rare skin disorder called Epidermolysis Bullosa, which it says offers a market opportunity worth more than $1 billion across the US and EU.

Amryt last year acquired Aegerion Pharmaceutical and last month listed on the Nasdaq.

It is also listed on Dublin's Euronext Growth and the AIM in London.

Its global headquarters are in Dublin, while its US operations are headquartered in Boston.

"The very positive momentum we experienced during 2019 and Q1 this year has been maintained through Q2 and I am pleased to report that our business continues to perform and grow beyond our expectations," said Amryt Pharma CEO Joe Wiley.  "Notwithstanding the obvious challenges we have faced in working through the very different environment presented by the Covid-19 pandemic.

"Our primary focus remains the health and well-being of our team, patients, carers, partners and their families."